Abstract
Drugs targeting genes that harbor natural variations associated with the disease the drug is in-
dicated for have increased odds to be approved. Various approaches have been proposed to iden-
tify likely causal genes for complex diseases, including gene-based genome-wide association stud-
ies (GWAS), rare variant burden tests in whole exome sequencing studies (Exome) or integration of
GWAS with expression/protein quantitative trait loci (eQTL-GWAS/pQTL-GWAS). Here, we compare
gene-prioritization approaches on 30 common clinical traits and benchmarked their ability to recover
drug target genes defined using a combination of five drug databases. Across all traits, the top pri-
oritized genes were enriched for drug targets with odds ratios (ORs) of 2.17, 2.04, 1.81 and 1.31 for
the GWAS, eQTL-GWAS, Exome and pQTL-GWAS methods, respectively. We quantified the perfor-
mance of these methods using the area under the receiver operating characteristic curve as metric,
and adjusted for differences in testable genes and data origins. GWAS performed significantly better
(54.3%) than eQTL (52.8%) and pQTL-GWAS (51.3%), but not significantly so against the Exome ap-
proach (51.7% vs 52.8% for GWAS restricted to UK Biobank data). Furthermore, our analysis showed
increased performance when diffusing gene scores on gene networks. However, substantial improve-
ments in the protein-protein interaction network may be due to circularity in the data generation process,
leading to the node (gene) degree being the best predictor for drug target genes (OR = 8.7, 95% CI
= 7.3-10.4) and warranting caution when applying this strategy. In conclusion, we systematically as-
sessed strategies to prioritize drug target genes highlighting promises and potential pitfalls of current
approaches.
2
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
Introduction1
Drugs whose targets have genetic support were found to be more likely to succeed in clinical trials [1, 2].2
Although multiple methods have been proposed to establish such genetic support, leveraging genetic3
data to find disease genes and ultimately drug targets has proven to be challenging [3, 4, 5, 6]. The4
most straightforward approach maps genome-wide association studies (GWASs) signals to the closest5
genes with more sophisticated methods incorporating linkage disequilibrium (LD) structure and gene6
annotation information to compute gene scores [7, 8, 9]. Over the past decade, large-scale molecular7
quantitative trait loci (mQTL) datasets facilitated the discovery of disease mechanisms and the identifi-8
cation of potential new drug targets [10, 11, 12, 13, 14, 15]. Several methods, including Mendelian ran-9
domization studies, transcriptome-wide association studies and colocalization methods have integrated10
expression and protein QTL data with GWAS studies to pinpoint likely causal genes for complex traits11
and diseases [16, 17, 18, 19, 20, 21, 22]. More recently, the availability of high-throughput sequencing12
data enabled the discovery and analysis of rare variants and their aggregated effects to reveal gene-13
disease associations [23, 24]. Whole exome sequencing (WES) in the UK Biobank (UKBB) showed that14
genes prioritized this way are 3.6 times more likely to be targets of drugs approved by the Food and15
Drug Administration (FDA) [25].16
17
Genes prioritised by GWASs, mQTL-GWAS integration methods and WES burden tests may not be18
drug targets themselves, but up- or downstream of those in pharmacological pathways. Propagating19
gene prioritization scores on networks has proven to be a promising approach to identify known drug20
target genes [26, 27, 28, 29, 30]. Starting from seed genes (i.e., prioritized disease-associated genes),21
network connectivity can identify neighbouring genes that strongly interact with disease genes, but lack22
a direct genetic evidence that explain their therapeutic effect. Gene networks can be derived from lit-23
erature or high-throughput experiments and thus are prone to yield very different results when used for24
(seed) gene score diffusion [31].25
26
Here, we took a comprehensive approach to examine the contribution of each method component27
3
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
to the success of drug target prioritization. First, we focused on four different approaches to prioritise28
(seed) genes: 1) LD-aware gene score computation from the largest GWASs with full publicly available29
summary statistics (Pascal [9]); 2) Mendelian Randomisation (MR) combining tissue-wide expression30
QTLs and GWAS (eQTL-GWAS); 3) MR combining plasma protein QTL with GWAS (pQTL-GWAS);31
4) UKBB WES burden tests (Exome). We then used three different networks to diffuse the seed32
gene scores: 1) STRING protein-protein interaction (PPI) network [32]; 2) an RNA-seq co-expression33
network [33]; 3) the FAVA network [34]. All 12 combinations of the four seed generating methods and the34
three networks were applied to thirty traits (Figure 1) using five different reference sets of target genes35
(DrugBank [35], Ruiz et al. [36], ChEMBL [37], DGIdb [38] and STITCH [39]). Overall, we provide an36
in-depth comparison of all combinations of these approaches, identifying their respective strengths and37
caveats.38
4
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
GWAS
GWAS p-values
QTL - GWAS
Gene
LD Reference
Gene scoring
GWAS
Mendelian randomization
pQTLs
- Tissue-wide
- Whole blood
- Plasma
Gene p-values
Exomea
Gene burden test
# variants
Trait
Gene p-values
Summary statistics Summary statistics
Rare variants (MAF ≤ 1%) in WES
Considered variants:
- putative loss-of-
function
- missense
Tsum = /uni2211z2
i
Tsum /uni223C/uni2211/uni03BBi /uni03C72
1
Protein
Transcript
eQTLs
pQTL b
GWAS b
/uni03B2MR
(Causal effect)
eQTL b
GWAS b
/uni03B2MR
Gene
0 1 2
b
eQTL-GWAS
pQTL-GWAS
Exome
GWAS
DGIdb
STITCH
ChEMBL
DrugBank
Ruiz et al.
ChEMBL
Drug target
genes
Prioritized
disease genes
Enrichment analysis (OR)
Area under the ROC curve (AUC)
Indication
Drug
c
Network diffusion
Protein-protein
interaction (STRING)
Co-expression
(CoXRNAseq)
Co-expression &
proteomics (FAVA)
Prioritized disease gene (GWAS, QTL-GWAS, Exome)
Drug target gene
slope =
network diffusion scores (x3)
network
diffusion scores
restart parameter r
(diffusion strength)
Gene p-values
Gene scores
5
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
Figure 1: Overview of the analysis workflow. a Three different gene prioritization methods were tested
in this study. The first one uses GWAS summary statistics as input (GWAS); the second combines
molecular QTL and GWAS summary statistics (QTL-GWAS): either expression QTL (eQTL) or protein
QTL (pQTL) data; the third leverages individual-level whole exome sequencing (WES) data (Exome).
In the GWAS method, gene p-values are based on the sum of squared SNP z-scores (T sum) that fol-
lows a weighted χ2
1 distribution. The QTL-GWAS method integrates QTL and GWAS summary statistics
through Mendelian randomization (MR). MR causal effect sizes (β MR) are calculated from GWAS and
mQTL effect sizes (GWAS b and mQTL b, respectively) and gene scores are the corresponding p-
values. The Exome method aggregates rare variants from WES data. Putative loss-of-function and
missense variants with minor allele frequencies (MAF) below 1% are collapsed in burden tests which
Results
in gene p-values. The different approaches were benchmarked for their ability to prioritize drug
target genes. b The effect of network diffusion using three different network types and different diffusion
strengths (i.e. restart parameter r) was evaluated. Drug target genes may only be prioritized following
signal propagation from neighboring disease genes. c Diseases were linked to target genes through
public drug databases: first, we used drug-indication information to connect the 30 traits to drugs and
then leveraged drug-target information to link the drugs to genes. Prioritized disease genes and cor-
responding diffusion scores (obtained via strategies described in panel a and b) were then tested for
overlap with drug target genes through Fisher’s exact tests resulting in odds ratios (ORs) and through
area under the receiver operating characteristic curve (AUC) values.
Results39
Overview of the analysis40
In this study, we calculated gene prioritization scores and tested their ability to identify drug targets41
across thirty traits (Figure 1). We focused on three types of methods termed GWAS, QTL-GWAS and42
Exome that allow the computation of gene scores provided genetic association data (Figure 1a).43
44
The GWAS method takes as input GWAS summary statistics together with a matching LD reference45
panel. Gene p-values are calculated based on the sum of squared test statistics for SNPs falling into46
the gene region [9]. The QTL-GWAS methods integrate GWAS summary statistics with molecular QTL47
data for the gene of interest. We calculated gene scores using i) expression QTL data (eQTL-GWAS )48
from the largest available whole blood eQTL study (eQTLGen study, n = 31,684) as well as tissue-wide49
eQTL data from the GTEx consortium v8 (n = 65-573 for 48 tissue types) and ii) protein QTL data50
(pQTL-GWAS) from the largest available plasma pQTL study (deCODE study, n = 35,559) [14] and i.51
Integration was done by performing Mendelian randomization (MR) analyses using either the protein52
6
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
or transcript as exposure and the GWAS trait as outcome. If not specified otherwise, the eQTL-GWAS53
Method
refers to the tissue-wide analysis in which the eQTLGen and GTEx data are combined by54
considering the tissue for which the MR effect was the most significant (Methods). While the GWAS55
and QTL-GWAS methods focuse on common genetic variants, the Exome method considers only56
rare variants from WES data with minor allele frequencies (MAF) below 1%. Gene scores were57
based on gene burden tests that aggregate putative loss-of-function and missense variants, and we58
used the resulting p-values from the WES analysis in the UKBB [25]. To allow for a fair comparison59
with the Exome method while also exploiting disease-specific consortia GWAS summary statistics60
with maximized case counts, we calculated gene prioritization scores for the GWAS and QTL-GWAS61
Methods
using both consortia GWAS and UKBB GWAS data (Table S1-3; Methods).62
63
Disease genes may not coincide with drug target genes, but they may be in close proximity in terms64
of molecular interaction (Figure 1b). Through diffusion based on random walks, we leveraged network65
connectivity to prioritize neighbours of disease genes, which may be drug targets. We tested this66
hypothesis on three different network types: the STRING PPI network which relies on literature67
interactions among other data types [32], a gene co-expression network based on 31,499 RNA-seq68
samples (CoXRNAseq ) [33], and gene co-expression network based on single cell RNA-seq and69
proteomics data (FAVA) [34]. Gene prioritization scores were obtained following diffusion at six different70
restart parameter values (r = 0, 0.2, 0.4, 0.6, 0.8, 1) (Methods).71
72
Disease drug target genes were defined using public databases. Specifically, drug-disease indica-73
tion were retrieved from DrugBank [35], Ruiz et al. [36], and ChEMBL [37], while drug-drug target74
pairs originate from DGIdb [38], STITCH [39], and ChEMBL [37]. Drug target enrichment analyses75
were calculated for the following five database combinations: DrugBank/DGIdb, DrugBank/STITCH,76
Ruiz/DGIdb, Ruiz/STITCH, and ChEMBL/ChEMBL.77
78
Finally, prioritized disease genes, defined as the top 1% of genes identified through the 12 combinations79
7
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
of gene prioritization and network diffusion methods (5% for combinations involving the pQTL-GWAS80
Method
to account for the smaller set of testable genes), were then tested for enrichment with the five81
drug target genes using Fisher’s exact test (Figure 1c). Background genes were defined as all genes that82
could be tested by the respective method, and sensitivity analyses were performed on background genes83
testable for all methods. Second, we calculated the area under the receiver operating characteristic84
curve (AUC) values which has the advantage of not requiring any thresholds. To compute a combined85
enrichment score per method, we aggregate results across traits and drug databases termed overall86
ORs or overall AUC values (Methods).87
Concordance of prioritized genes among gene scoring methods88
We first analyzed whether genes prioritized by the GWAS, QTL-GWAS and Exome methods were89
concordant (Figure 2). For each of the thirty traits (Figure 2a), we calculated gene scores for the90
testable autosomal protein-coding genes (GWAS: ∼19,150, eQTL-GWAS: ∼12,550 (blood) and ∼16,25091
(tissue-wide), pQTL-GWAS: ∼1,870, Exome: ∼18,800). In the tissue-wide eQTL-GWAS method, the92
tissue with the most significant MR p-value was selected. In Figure S1, we show the proportion of genes93
mapped to a particular tissue category. The contribution of glandular-endocrine, neural central nervous94
system (CNS) and whole blood (eQTLGen) tissue categories were the highest (respective means of95
15.3%, 12.8%, and 12.6% across the thirty traits; Table S4-5). Although each trait had genes mapped96
to nearly all tissues, a few distinctive patterns could be observed: cardiac muscle tissues contributed97
the most to atrial fibrillation (16.4%), vascular tissues the most to coronary artery disease (16.5%)98
followed by diastolic (11.1%) and systolic (9.9%) blood pressure, and the neural CNS contributed the99
most to schizophrenia (16.9%) and bipolar disease (16.6%).100
101
8
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
0
2
4log−OR
Alzheimer
Asthma
Atopic dermatitis
Atrial fibrillation
Bipolar
CAD
CKD
COPD
Diastolic BP
Endometriosis
Epilepsy
Glaucoma
IBD
IBS
LDL
MDD
Multiple sclerosis
Osteoarthritis
Osteoporosis
Parkinson's disease
Pneumonia
Psoriasis
Rheumatoid arthritis
Schizophrenia
Stroke
Systolic BP
T1D
T2D
Total cholesterol
VTE
0.0
2.5
5.0
7.5
10.0
0.0 2.5 5.0 7.5 10.0
Top gene percentile (%)
log−OR
eQTL−GWAS vs GWAS
0.0
2.5
5.0
7.5
10.0
0.0 2.5 5.0 7.5 10.0
Top gene percentile (%)
log−OR
GWAS vs Exome
0.0
2.5
5.0
7.5
10.0
0.0 2.5 5.0 7.5 10.0
Top gene percentile (%)
log−OR
eQTL−GWAS vs Exome
0.0
2.5
5.0
7.5
10.0
0.0 2.5 5.0 7.5 10.0
Top gene percentile (%)
log−OR
eQTL−GWAS vs pQTL−GWAS (blood)
Alzheimer
Asthma
Atopic dermatitis
Atrial fibrillation
Bipolar
CAD
CKD
COPD
Diastolic BP
Endometriosis
Epilepsy
Glaucoma
IBD
IBS
LDL
MDD
Multiple sclerosis
Osteoarthritis
Osteoporosis
Parkinson's disease
Pneumonia
Psoriasis
Rheumatoid arthritis
Schizophrenia
Stroke
Systolic BP
T1D
T2D
Total cholesterol
VTE
0.2
0.3
0.4
0.5
0.6
0.7
Q1 Q2 Q3 Q4
Transcript Heritability − quartile
Spearman ρ
eQTL−GWAS vs GWAS
0.1
0.2
0.3
0.4
Q1 Q2 Q3 Q4
Transcript Heritability − quartile
Spearman ρ
eQTL−GWAS vs pQTL−GWAS (blood)
a b
c d
9
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
Figure 2: Evaluating the concordance of prioritized genes among methods. a Thirty different traits/drug
indications were tested in this study. b The top prioritized genes between pairs of methods were com-
pared at different thresholds for each trait (legend shown in a). The logarithm of odds ratios (log-OR)
were calculated from Fisher’s exact tests. Log-ORs are only plotted for percentiles at which common
genes between pairs of methods were found. Comparisons were conducted on the same background
genes and same data origins (i.e., on UK Biobank GWASs for comparisons with the Exome method).
Tissue-wide eQTL-GWAS gene prioritizations were considered for the comparison with the GWAS and
Exome methods, and the blood-only eQTL-GWAS gene prioritization method for the comparison with
the pQTL-GWAS method. c Spearman correlations calculated per trait between the gene significance
(-log10(p-values)) from the GWAS and tissue-wide eQTL-GWAS methods. The analysis was conducted
per trait on all common genes ( ∼16,100) stratified into quartiles according to transcript heritability (in
cis). d Spearman correlations calculated per trait between gene Mendelian randomization (MR) causal
effect sizes (βMR) from the blood eQTL-GWAS and pQTL-GWAS methods. The analysis was conducted
on all common genes (∼1,370) stratified into quartiles according to the transcript heritability. In c and d,
the boxplots bound the 25th, 50th (median, centre), and the 75th quantile. Whiskers range from minima
(Q1 – 1.5 · IQR) to maxima (Q3 + 1.5 · IQR) with points corresponding to individual traits from a.
The concordance of prioritized genes among pairs of methods is summarized in Figure 2b. For each102
trait, we calculated Fisher’s exact tests between the top prioritized genes at thresholds ranging from the103
top 0.1%-10% (Methods). The overlap was the highest between the GWAS and eQTL-GWAS methods.104
At 1%, the median odds ratio (OR) was 212.2 which dropped to 51.0 and 22.1 at 5% and 10%, respec-105
tively. The concordance between GWAS and eQTL-GWAS prioritized genes was highest for transcripts106
with high heritabilities (Figure 2c; Methods). Similarly, the agreement between the eQTL-GWAS (whole107
blood) and pQTL-GWAS (blood plasma) increased with increasing transcript heritabilities (Figure 2d).108
Overall, the median ORs between these two methods was 8.5 and 4.6 at the top 5% and 10%, respec-109
tively. The overlap of prioritized genes was the lowest with the Exome method. The top 1% GWAS vs110
Exome and eQTL-GWAS vs Exome overlaps (based only on UKBB GWAS summary statistics), yielded111
median ORs of 1.7 and 1.9, respectively which dropped to 1.0 at 10% for both methods.112
Enrichment of prioritized genes for drug targets113
Next, we assessed the extent to which prioritized genes overlapped with drug target genes. For114
each trait, we conducted enrichment analyses for the GWAS, eQTL-GWAS, pQTL-GWAS and Exome115
Methods
using our five definitions of drug target genes.116
10
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
117
In Figure 3a, we show the resulting ORs for the DrugBank/DGIdb database combination. Across118
methods, genetic support for drug targets was the highest for LDL and total cholesterol (average ORs119
of 5.99 and 6.12, respectively). Lowest enrichment ratios were obtained for neuro-psychiatric traits120
(average OR of 1.56) and glaucoma (average OR of 1.14). The average OR across traits was 2.48,121
2.68, 1.65, and 1.26 for the GWAS, eQTL-GWAS, Exome and pQTL-GWAS methods, respectively.122
We explored a range of top disease gene percentiles (0.1-5%) and the corresponding ORs are123
shown in Figure 3b. Restricting disease genes to the top 0.1% for all methods increased the average124
ORs without changing the method ranking with average ORs of 3.68, 4.02, 2.40, and 1.44 for the125
GWAS, eQTL-GWAS, Exome and pQTL-GWAS methods, respectively. We further analyzed whether126
identified drug targets were the same across methods and found that prioritized drug target genes were127
similar between GWAS and eQTL-GWAS methods (average Jaccard index of 0.39), less so between128
eQTL-GWAS and pQTL-GWAS methods (blood tissues; average Jaccard index of 0.15) and were very129
different from Exome identified targets (average Jaccard index of 0.06 between GWAS & Exome and130
eQTL-GWAS & Exome methods). Average AUC values across traits were of 53.4%, 51.9%, 50.5% and131
49.9% for the GWAS, eQTL-GWAS, Exome and pQTL-GWAS methods (Figure 3c).132
133
While the number of drugs reported per indication was similar across databases (average of 43.9,134
41.8 and 40.4 for Ruiz et al., ChEMBL and DrugBank, respectively), the average number of reported135
drug targets was much higher for Ruiz/STITCH (285), Ruiz/DGIdb (274.8), Drugbank/DGIdb (263.4)136
and Drugbank/STITCH (244.2) than for ChEMBL/ChEMBL (24.8; Table S7). We repeated drug target137
enrichment calculations for all drug database combinations (Figure 3d, Figure S2). The average OR138
for the GWAS/eQTL-GWAS methods were 2.48/2.68, 2.80/2.53, 2.18/2.12, 1.78/1.61 and 1.78/1.51 for139
Drugbank/DGIdb, ChEMBL/ChEMBL, Ruiz/DGIdb, Ruiz/STITCH and Drugbank/STITCH, respectively.140
Overall, the variability in ORs across traits was the highest in the ChEMBL database (Figure 3d, Figure141
S2), likely due to the low average number of reported drug targets which leads to very high ORs when142
drug targets figured among the prioritized genes (e.g. for LDL and total cholesterol), but for many traits143
11
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
drug target genes were not among prioritized genes (e.g. for type 1 diabetes, atopic dermatitis and144
inflammatory bowel disease).145
146
Since enrichment results can differ widely across traits and reference databases, we calculated overall147
enrichment and AUC values across traits and drug databases, including sensitivity analyses on UKBB148
data only and common background genes (Table S9, Figure S4; Methods). The overall ORs were 2.17149
(UKBB: 1.72), 2.04 (UKBB: 1.67), 1.81 and 1.31 (UKBB: 1.30) for the GWAS, eQTL-GWAS, Exome and150
pQTL-GWAS methods, respectively. There were no significant differences between these four methods151
in terms of enrichment OR (Pdiff > 0.05 including in the sensitivity analyses). Overall AUCs were 54.3%152
(UKBB: 52.8%), 52.8% (UKBB: 51.4%), 51.7% and 51.3% (UKBB: 50.6%) for the GWAS, eQTL-GWAS,153
Exome and pQTL-GWAS methods, respectively. Judging by the AUC values, GWAS performed signifi-154
cantly better than eQTL-GWAS (Pdiff = 3.1e-5) also when only considering testable eQTL genes (P diff =155
2.9e-4). Significantly higher AUC values were obtained for the GWAS compared to Exome on consortia156
data (Pdiff = 2.2e-4) which was no longer the case on UKBB data (P diff = 0.06). The difference between157
eQTL-GWAS and Exome was not significant on either dataset (P diff of 0.12 and 0.77 on consortia and158
UKBB data, respectively). The number of testable genes was much lower for the pQTL-GWAS method159
(∼1,870 genes). With this set of background genes, GWAS still scored a higher overall AUC (55.1%,160
Pdiff = 2.1e-3). No difference was observed between the pQTL-GWAS and tissue-wide or whole blood161
eQTL-GWAS methods (Pdiff of 0.66 and 0.87, respectively).162
12
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
0.35
0.40
0.45
0.50
0.55
0.60
GWAS eQTL−GWAS Exome pQTL−GWAS
AUC
0
10
20
0 1 2 3 4 5
Top gene percentile (%)
OR
GWAS
eQTL−GWAS
Exome
pQTL−GWAS
Panel a,d*
*pQTL-GWAS
1
8
64
DrugBank /
DGIdb
Ruiz /
DGIdb
Ruiz /
STITCH
DrugBank /
STITCH
ChEMBL /
ChEMBL
OR
Glaucoma
Bipolar
MDD
Schizophrenia
Alzheimer
Parkinson's disease
Epilepsy
Multiple sclerosis
Pneumonia
COPD
Asthma
IBS
IBD
Psoriasis
Atopic dermatitis
Osteoarthritis
Osteoporosis
Rheumatoid arthritis
Stroke
Atrial fibrillation
Diastolic BP
Systolic BP
CAD
VTE
Endometriosis
CKD
T1D
T2D
Total cholesterol
LDL
eQTL−GWAS vs
GWAS
GWAS vs ExomeeQTL−GWAS vs
Exome
eQTL−GWAS vs
pQTL−GWAS (blood)
1.00 0.75 0.50 0.25 0.00
eQTL−GWAS vs Exome
GWAS vs Exome
eQTL−GWAS vs pQTL−GWAS
eQTL−GWAS vs GWAS
EndometriosisRheumatoid arthritis
OsteoporosisMultiple sclerosis
Parkinson's disease
Total cholesterol
PsoriasisAtrial fibrillation
Glaucoma
IBS
MDDSystolic BP
LDL
CKD Diastolic BP
Asthma
IBD
CAD
T2D
Schizophrenia
Atopic dermatitis
VTE
Osteoarthritis
Bipolar
Epilepsy
COPDAlzheimer
Pneumonia
Stroke
T1D
Jaccard index
1.00
0.75
0.50
0.25
0.00
Common identified drug targets
1
4
2
1
0
4
3
4
2
7
5
4
1
4
4
7
0
0
2
0
1
0
3
2
2
1
6
4
3
7
11
10
0
2
4
1
2
1
2
2
5
2
5
9
2
1
2
1
6
3
8
11
2
5
8
9
6
2
4
10
4
2
4
4
1
5
6
6
10
12
18
18
5
9
0
8
4
3
7
8
6
10
14
16
8
13
20
17
5
7
11
13
5
7
4
7
0
0
1
1
1
2
4
6
1
2
1
1
6
8
9
10
6
15
13
13
6
13
13
14
Glaucoma
Bipolar
MDD
Schizophrenia
Alzheimer
Parkinson's disease
Epilepsy
Multiple sclerosis
Pneumonia
COPD
Asthma
IBS
IBD
Psoriasis
Atopic dermatitis
Osteoarthritis
Osteoporosis
Rheumatoid arthritis
Stroke
Atrial fibrillation
Diastolic BP
Systolic BP
CAD
VTE
Endometriosis
CKD
T1D
T2D
Total cholesterol
LDL
0 2 4 6 8
OR
MetabolicGenito-
urinaryCirculatory systemMusculoskel. &
connect. tissueSkinDigestive
systemRespiratoryNervous systemPsychiatricEye
a
# Identified
drug targets
GWAS
eQTL-GWAS
Exome
pQTL-GWASICD10
classification
b
c
eQTL-GWAS &
GWAS GWAS & Exome
eQTL-GWAS &
Exome
eQTL-GWAS &
pQTL-GWAS (blood)
Jaccard index
1.000.750.500.250.00
Common identified drug targets
d
13
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
Figure 3: Enrichment for drug target genes. a Left: Barplot with odds ratios (ORs) calculated from
Fisher’s exact tests between drug target genes and the top 1% (5% for pQTL-GWAS) prioritized genes
for the four tested methods and thirty traits, classified according to trait category. Drug target genes were
defined by DrugBank/DGIdb, and only drug target genes that could be tested by the respective method
were considered. The number on the right of each bar indicates the number of identified drug target
genes. Right: Overlap of identified drug target genes between pairs of methods quantified through the
Jaccard index. The blood-only eQTL-GWAS gene prioritization method was used for the comparison
with the pQTL-GWAS method. Plots using UKBB GWASs-only are shown in Figure S3. b ORs at
different top prioritised gene percentiles for the four methods. The plotted dots correspond to the median
OR across the thirty traits, and the shaded area bounds the 10% and 90% percentiles. c Boxplots
showing the area under the receiver operating characteristic curve (AUC) values. AUC values were
calculated for each trait as indicated by the points (legend in Figure 2a) and using the same background
genes and drug target definitions as in a. d ORs calculated for the five drug target definitions and for
all four methods (legend in b). The OR was set to 1 for traits with no identified drug target genes. In b
and d, the boxplots bound the 25th, 50th (median, centre), and the 75th quantile. Whiskers range from
minima (Q1 – 1.5 · IQR) to maxima (Q3 + 1.5 · IQR) with points outside representing potential outliers.
Examples of drug target prioritization ranks163
In Figure 4, we highlight drug targets and their gene prioritization ranks for a few examples (complete list164
in Table S10). Major antihypercholesterolemic drug targets PCSK9 (evolocumab, alirocumab), HMGCR165
(statins) and NPC1L1 (ezetimibe) were top ranked by all methods (except for no pQTLs being available166
for HMGCR and NPC1L1; Figure 4a). HCN4, the target of antiarrhythmic drug dronedarone, was priori-167
tized as a disease gene for atrial fibrillation only through the GWAS method. Although highly expressed168
in the atrial appendage and left ventricle of the heart, no eQTL was reported for this gene (Figure 4b).169
Several antiepileptic drugs target SCN1A which was highly prioritized by the GWAS and eQTL-GWAS170
Methods
with the strongest MR effect found in the nucleus accumbens (basal ganglia) of the brain (Fig-171
ure 4c). Antiplatelet drug dipyrimadole used in the prevention and treatment of vascular diseases such172
as stroke and coronary artery disease is listed to target 23 genes of the PDE superfamily in ChEMBL.173
Of these, four (PDE4D, PDE3A, PDE3B, PDE6B) were ranked in the top 1% by the exome method for174
stroke (Figure 4d). None of the other methods prioritized any of these 23 genes. For coronary artery dis-175
ease, another superfamily member (PDE5A) had a low ranking (< 2%) for the GWAS and QTL-GWAS176
methods, supported by solid GWAS and e/pQTL colocalisation (Figure 4e).177
14
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
da
b
Dipyri-
damole
Drone-
darone
PCSK9
HMGCR
PDE3B
PDE4D
NPC1L1
HCN4
StrokeLDL
Atrial
fibrillation
25 (0.15%)
18 (0.92%)
1 (<0.01%)
1-52 (<0.01%)
1-52 (<0.01%)
12 (0.07%)
no pQTL
10 (0.05%)
53 (0.33%)
NA
5 (0.03%)
175 (0.92%)
no eQTL
eQTL-GWAS
NA
pQTL-GWAS
9,010 (47.9%)
Exome
12 (0.06%)
GWAS
Artery - Aorta
Artery - Coronary
Artery - Tibial
Brain - Amygdala
Brain - Ant. cing. cortex
Brain - Caudate (basal ganglia)
Brain - Cerebellar Hemisphere
Brain - Cerebellum
Brain - Cortex
Brain - Frontal Cortex (BA9)
Brain - Hippocampus
Brain - Hypothalamus
Brain - Nuc. acc. (basal ganglia)
Brain - Putamen (basal ganglia)
Brain - Spinal cord (cervical c-1)
Brain - Substantia nigra
Heart - Atrial Appendage
Heart - Left Ventricle
Pituitary
Testis
Whole Blood
0
10
20
30
40
TPM
Bulk tissue gene expression for HCN4
> 18%
> 12%
no pQTL / NA
< 1%
c
SCN1AEpilepsy
13 (0.08%)
no pQTL
472 (2.5%)
2 (<0.01%)
e
Brain − basal ganglia
Brain − cortex
Brain cerebellum
Testis
−0.025 0.000 0.025 0.050
MR effect size
Position on chrom 4 [Mb]
−log10(PGWAS)
0 2 4 6 8 10
Position on chrom 4 [Mb]
−log10(PpQTL)
0 20 40 60 80 100 120
Position on chrom 4 [Mb]
−log10(PeQTL)
0 10 20 30 40 50
120.0 120.2 120.4 120.6 120.8
Position on chrom 4 [Mb]
Position on chr 4 [Mb]
0
5
10
15
− log10(p−value)
0
20
40
60
80
100
Recombination rate (cM/Mb)
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF
/uni25CF/uni25CF/uni25CF
/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF/uni25CF
/uni25CF
rs7678555
0.2
0.4
0.6
0.8
r2
MYOZ2
USP53
C4orf3
FABP2
LINC01061
LOC645513
PDE5A
LINC01365 MAD2L1
120 120.2 120.4 120.6 120.8 121
Position on chr4 (Mb)
Plotted SNPs
PDE5ACAD
150 (0.9%)
30 (1.6%)
7,212 (38.3%)
285 (1.5%)Dipyri-
damole
> 5%
> 1%
> 1%
> 1%
PDE3A
PDE6B
15
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
Figure 4: Examples illustrating drug target genes and their prioritization ranks. a Three drug target
genes (PCSK9 (evolocumab, alirocumab), HMGCR (statins) and NPC1L1 (ezetimibe) shown in purple)
for LDL cholesterol (blue box) and their prioritization ranks (top percentiles shown in parentheses) of
each of the four methods (GWAS in green, eQTL-GWAS in yellow, Exome in blue and pQTL-GWAS
in red). Genes that were not testable by a given method are reported as NA (no e/pQTL means that
the gene was measured, but had no QTL) and a range of ranks (i.e., 1-52) indicates tied p-values. b
Top plot shows the prioritization ranks of HCN4, the target of antiarrhythmic drug, dronedarone. Bot-
tom plot shows the gene expression profile of HCN4 across GTEx tissues (transcript per million - TPM)
with “Testis”, “Heart – Atrial Appendage” and “Heart – Left Ventricle” dominating.c Top plot shows the
prioritization ranks of SCN1A (Sodium Voltage-Gated Channel Alpha Subunit 1), a drug target gene of
several antiepileptic drugs. Bottom plot shows Mendelian randomization (MR) effects (red dot) wih 95%
CI (black bars) across tissues in which there was a significant eQTL. d Antiplatelet drug dipyrimadole
and gene prioritization ranks of its multiple drug targets (a non-exhaustive selection) of the phosphodi-
esterase (PDE) superfamily. e Top plot shows the gene prioritization ranks of PDE5A, another reported
target for dipyrimadole. Bottom plot shows the regional SNP associations (-log 10(p-values)) with coro-
nary artery disease (CAD; GWAS, green), PDE5A protein (pQTL, red) and PDE5A transcript (eQTL,
yellow), respectively (red dashed lines indicate the significance thresholds of the respective SNP asso-
ciation, and grey shade marks the position of PDE5A). Bottom row illustrates the positions and strand
direction of the genes in the locus.
Heritability and polygenicity of drug target transcripts and proteins178
It has been shown that drug target genes are more likely to have lower residual variance intolerance179
scores (RVIS), i.e., are less tolerant to change [1]. With the availability of large-scale eQTL and pQTL180
data, we tested whether drug target transcript or protein levels may be less impacted by genomic181
variations.182
183
To this end, we compared cis-heritabilities and polygenicities of drug target genes versus non-drug184
target genes that were measured in the respective studies (i.e., also those with no reported e/pQTLs;185
Methods). We conducted the analysis per trait and for each of the five drug target gene definitions.186
Overall, we observed that drug target genes were less heritable and more polygenic than non-drug187
target genes pointing towards a negative selection [40] (Figure S5). This trend was less pronounced188
for tissue-wide than for whole blood eQTLs, and was the strongest for pQTLs. Across QTL studies and189
drug databases, the traits for which drug targets were significantly less heritable and more polygenic190
differed substantially. However, in no scenario drug target genes were more heritable than non-drug191
target genes on either the transcript or protein-level (at a nominally significant level). Considering drug192
16
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
target genes defined by DrugBank/DGIdb for the plasma protein QTLs as an example: targets for traits193
from the circulatory system were all shown to be more polygenic, and targets for psychiatric traits were194
all less heritable at a nominally significant level.195
Network diffusion196
Finally, we assessed whether network diffusion can identify drug target genes for which there is no197
direct genetic evidence. Gene scores from prioritization methods defined the initial distribution p0 of198
the diffusion process. This process is regulated by a restart parameter r where lower values result in a199
wider diffusion (i.e., genes can be prioritized even when distant from initial disease genes; Methods).200
The stationary distribution was calculated for six different restart parameters, ranging from no diffusion201
(r = 1) to complete diffusion (r = 0). Since the set of testable proteins ( ∼1,870) is enriched for drug202
target genes (two-sided binomial test: p-value = 1.3e-47 for DrugBank/DGIdb; complete results in Table203
S15; Methods) AUC values were artificially inflated upon projecting the gene scores onto the network204
and pQTL-GWAS results are hence not discussed.205
206
Applying diffusion using the STRING network massively boosted the overlap between the diffused207
prioritized genes and the drug target genes (Figure 5a-b, Figure S6-7). At no diffusion, overall AUC208
values across the thirty traits were 54.3%, 52.8% and 51.7% for the GWAS, eQTL-GWAS and Exome209
methods, respectively, which increased to 68.9%, 67.7% and 66.9% at r = 0.6, and 73.5%, 72.9% and210
72.3% at r = 0.4 (Figure 5a, Figure S6, Table S12). The same trend was observed when calculating211
enrichment scores for the top 1% genes with overall ORs of 4.63, 5.21 and 5.07 at r = 0.4 (Figure 5b,212
Figure S7, Table S12). On the other hand, improvements were modest when considering co-expression213
networks. At r = 0.6, overall AUC values increased to 54.9%, 54.7% and 53.5% in case of the214
CoXRNAseq network. Although small, the difference was significant compared to no diffusion (P diff of215
5.11e-3, 4.12e-14 and 4.83e-5, respectively). Overall ORs at r = 0.6 were 2.28, 2.04 and 1.91 which216
were not significantly different (P diff > 0.05) compared to no diffusion. Likewise, in the FAVA network,217
overall AUC values at r = 0.6 were 55.9%, 54.2% and 53.6% (Pdiff compared to no diffusion of 2.23e-5,218
17
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
3.08e-3 and 7.3e-6), and ORs 2.38, 2.02 and 1.77 (P diff > 0.05) for GWAS, eQTL-GWAS and Exome219
methods, respectively (Figure S6-7, Table S12-13).220
221
We further assessed which method’s AUC values benefited the most from network diffusion. To allow222
fair comparisons with the Exome methods, we used UKBB GWAS data for the GWAS and eQTL-GWAS223
methods. Across all diffusion parameters r, overall AUC values were significantly higher for GWAS224
than eQTL-GWAS in the STRING and FAVA network (P diff 0.05). A nominally significant difference in favour of GWAS compared226
to Exome was only observed in the STRING network at r values of 0.4, 0.6 and 0.8 (P diff of 0.0262,227
7.36e-3 and 0.0146, respectively). No statistical differences were observed between the eQTL-GWAS228
and Exome method except for a nominally significant difference in favour of eQTL-GWAS at r = 0.2 in229
the CoXRNAseq network (Pdiff = 0.0113).230
231
When investigating the network connectivity, we observed that drug target genes were significantly more232
likely to be hub genes (Figure 5c, Figure S8). This observation was particularly strong in the STRING233
network (mean log-degree = 13.0 vs 12.3, Pdiff = 6.6e-284 for DrugBank/DGIdb), but also present in the234
co-expression networks (∆ log-degree = 0.064, Pdiff = 0.011 for CoXRNAseq; ∆ log-degree = 0.3, Pdiff235
= 6.6e-11 for FAVA). As a consequence, the network’s node degree was found to be a good predictor236
of drug targets, and the best performance was found for the network degree in STRING (overall AUC =237
77.6%, overall OR = 8.71). Given this bias, we generated random initial disease gene scores and de-238
termined to which extent genetically-informed p0 distributions performed better compared to random p0239
distributions. Although GWAS, eQTL-GWAS and Exome methods had significantly higher AUC values240
than random score distributions for any givenr value in the STRING network (Pdiff < 1.62e-7; Table S13),241
the performance of a mildly diffused (r= 0.8) random score (which is unaware of the target disease) per-242
formed significantly better than any disease gene prioritisation method without diffusion (Pdiff of 4.18e-6,243
3.58e-10 and 2.10e-12 compared to GWAS, eQTL-GWAs and Exome, respectively). In line with this244
observation, the network degree was still significantly better than gene prioritization methods at r = 0.2245
18
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
(Pdiff of 8.98e-6, 9.87e-13 and 1.89e-11 compared to GWAS, eQTL-GWAs and Exome, respectively).246
0.5
2.0
8.0
1 0.8 0.6 0.4 0.2 0
restart parameter r
OR
STRING
0.5
2.0
8.0
1 0.8 0.6 0.4 0.2 0
restart parameter r
OR
CoXRNAseq
0.5
1.0
2.0
4.0
8.0
1 0.8 0.6 0.4 0.2 0
restart parameter r
OR
FAVA
GWAS eQTL−GWAS Exome pQTL−GWAS Random
0
1000
2000
7.5 10.0 12.5 15.0
log−degree
Gene count
STRING ; ∆ = 0.75 ; p = 6.6e−284
0
500
1000
1500
2 4 6 8
log−degree
Gene count
CoXRNAseq ; ∆ = 0.064 ; p = 0.011
0
200
400
600
7 9 11 13
log−degree
Gene count
FAVA ; ∆ = 0.3 ; p = 6.6e−11
Drug target gene
no yes
0.4
0.5
0.6
0.7
0.8
1 0.8 0.6 0.4 0.2 0
restart parameter r
AUC
STRING
0.4
0.5
0.6
0.7
0.8
1 0.8 0.6 0.4 0.2 0
restart parameter r
AUC
CoXRNAseq
0.4
0.5
0.6
0.7
0.8
1 0.8 0.6 0.4 0.2 0
restart parameter r
AUC
FAVA
GWAS eQTL−GWAS Exome pQTL−GWAS Random
a
b
No diffusion Network
degree
No diffusion Network
degree
c
19
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
Figure 5: Effect of network diffusion to prioritize drug target genes. a Boxplots showing the area under
the receiver operating characteristic curve (AUC) values for each network type (STRING, CoXRNAseq
and FAVA) and method at different restart parameter values r. AUC values were calculated for each
of the thirty traits, and drug target genes were defined by DrugBank/DGIdb. At an r value of 1 (no
network diffusion), the analysis corresponds to the results in Figure 3b, and at an r value of 0, the gene
prioritization rank is simply based on the degree of the network nodes. At r < 1, the background genes
are the genes reported in the respective network. The star next to the pQTL-GWAS method signals that
the set of testable genes for this method is enriched for drug target genes and therefore higher AUC
values were obtained when adding background genes with zero-valued initial scores. b Odds ratios
(ORs) between prioritized genes (top 1%) and drug target genes for each network type and method at
different r values across the thirty traits (same drug target and background genes as in a). The OR was
set to 1 for traits with no identified drug target genes. c Histograms showing the degree distribution of
drug target genes and non-drug target genes in each network. The difference in log-degree (∆) and the
p-values from two-sided t-tests are shown in the titles. In a and b, the boxplots bound the 25th, 50th
(median, centre), and the 75th quantile. Whiskers range from minima (Q1 – 1.5 · IQR) to maxima (Q3 +
1.5 · IQR) with points above or below representing potential outliers.
Examples of prioritized genes through network diffusion247
In the following, we describe several examples for which drug targets figured among the top 1% genes248
only after network diffusion (complete list in Table S14). Amyloid-beta precursor protein (APP) targeted249
by the monoclonal antibody aducanumab in the treatment of Alzheimer’s disease was ranked 506 (top250
2.7%) prior and 152 (top 0.8%) after diffusion on the STRING network (r = 0.6; Figure 6a) based on the251
eQTL-GWAS method. Prioritization was largely influenced by its interacting neighbour Apolipoprotein E252
(APOE) which was the top 5 ranked gene for Alzheimer’s disease. Tumor necrosis factor (TNF), a drug253
target in the treatment of inflammatory diseases such as psoriasis, was ranked 1,558 (top 8%; Exome-254
Psoriasis) prior and 182 (top 0.98%; r = 0.6) post-propagation in the STRING network (Figure 6b).255
While initially the drug target F2 (Coagulation Factor II, Thrombin) for VTE (venous thromboembolism)256
ranked only in the top 2% it moved up to the top 1% regardless of the network used for diffusion at r =257
0.6 (top 0.9%, 0.6% and 0.7% for STRONG, CoXRNAseq and FAVA, respectively). In the STRING and258
CoXRNAseq networks, this boost could largely be attributed to the interacting fibrinogen genes (FGA,259
FGB and FGG) that ranked in the top 0.06% (Figure 6c).260
20
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
APP
NCSTN
APH1A
PSEN1
APBA2
APBB1
BACE1
APBA1
SORL1
APOE NAE1
FGB
FGA
AHSG
UGT2B10
F2 ITIH2
APOH
SLC17A2
C8A
APOA2
ALB
FGB
FGA
AHSG
UGT2B10
F2 ITIH2
APOH
SLC17A2
C8A
APOA2
ALB
C4A
C4B
ITIH4
ITIH2 F12
C7
F2
VTN
SERPINF2
PLG
KNG1
C4A
C4B
ITIH4
ITIH2 F12
C7
F2
VTN
SERPINF2
PLG
KNG1
F2
FGG
FGB
FGA
THBD
SERPINC1
SERPIND1
F2R
F2RL3
CPB2
F2RL2
F2
FGG
FGB
FGA
THBD
SERPINC1
SERPIND1
F2R
F2RL3
CPB2
F2RL2
a b
c
r = 1
r = 0.6
VTE
STRING CoXRNAseq FAVA
GWAS
r = 0.6
r = 1
STRING
eQTL-GWAS
Exome
Psoriasis
STRING
r = 1
r = 0.6
TNF
TNFRSF1A RIPK1
TRADD
TNFRSF1B
TRAF2
F ADD
IKBKB
IL10
IL6
IL4
TNF
TNFRSF1A RIPK1
TRADD
TNFRSF1B
TRAF2
F ADD
IKBKB
IL10
IL6
IL4
APP
NCSTN
APH1A
PSEN1
APBA2
APBB1
BACE1
APBA1
SORL1
APOE NAE1
1.2e−05 4.5e−04
1.2e−05 2.5e−03
Alzheimer
7.5e−06 2.8e−03
21
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
Figure 6: Examples illustrating network diffusion to prioritize drug target genes. a Top ten network
neighbours of drug target APP (brown circle) and their prioritization values (i.e., normalized node proba-
bilities) of the eQTL-GWAS method for Alzheimer’s disease are shown before (r= 1) and after diffusion
(r = 0.6) on the STRING network. b Same representation as in a showing Exome prioritization values
for psoriasis and tumor necrosis factor (TNF) drug target. c Top ten network neighbours of drug target
F2 (Coagulation Factor II, Thrombin) in the STRING, CoXRNAseq and FAVA networks. GWAS prioriti-
zation values for venous thromboembolism (VTE) are shown before (r = 1) and after diffusion (r = 0.6)
on each network. In each network example (a-c), the drug target gene was among the top 1% prioritized
genes only after diffusion at r = 0.6.
Discussion261
We conducted a comprehensive benchmarking between different genetically informed approaches262
(GWAS, QTL-GWAS and Exome) combined with network diffusion to prioritize drug target genes.263
The strength of our analysis lies in the side-by-side comparison of gene prioritization methods that264
individually have proven to be successful in identifying drug targets. Recently, methods have emerged265
that combine multiple genetic predictors to derive an aggregate score often using machine-learning266
techniques [27, 41, 42]. These scores demonstrated high enrichment for drug targets but reveal little267
about underlying molecular mechanisms. Our aim was to disentangle the importance of the choice of268
the ground truth (i.e., drug target genes), the input data (such as molecular QTLs, WES) in combination269
with different molecular networks to highlight added benefits while also exposing weaknesses compared270
to using GWAS data alone.271
272
Adjusting for differences in background genes and data origins, GWAS yielded higher AUC than273
eQTL- and pQTL-GWAS, but no significant difference was found with Exome. Genes prioritized by274
the Exome method were different from those identified by the GWAS and QTL-GWAS methods which275
was also reflected in the identified drug targets. While this could imply that rare- and common variant276
genetic architectures are complementary, differences could also be due to power issues. Possibly,277
with increased sample size the implicated genes will converge, but the extent to which they can be278
perturbed by regulatory vs rare coding variants might remain different. Considering ORs, we lacked279
statistical power to claim significant differences between methods since the number of drug targets280
22
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
among top 1% prioritized genes can be very low. Overall enrichment ORs for drug targets were 2.17,281
2.04, 1.81 and 1.31 for the GWAS, eQTL-GWAS, Exome and pQTL-GWAS methods, respectively.282
Although ORs for the pQTL-GWAS method may seem lower, it should be noted that testable proteins283
(i.e., proteins with pQTLs) accounted for ∼10% of GWAS testable genes. On the same background284
genes, ORs for the tissue-wide and blood-only eQTL-GWAS methods were 1.38 and 1.22, respectively.285
For the AUC metric, no significant difference between eQTL-GWAS and pQTL-GWAS was found. In286
the method comparisons, we considered multiple drug target gene definitions. The number of targets287
per drug drastically differed between ChEMBL and the DGIdb or STITCH databases due to differences288
in their construct. Drug target genes in the ChEMBL database are manually curated and should not289
contain false positives but it remains debatable whether to consider only primary or also secondary290
target genes. For instance, ChEMBL only lists HMGCR as a drug target for statins, whereas the DGIdb291
database also includes APOA5, APOB and APOE among others. For this reason, we considered292
different databases and present enrichment results for both broad and narrow drug target definitions,293
as well as aggregates.294
295
Network diffusion was beneficial for prioritizing drug target genes with weaker genetic support. A296
remarkable increase in drug target identification was achieved when using the STRING network.297
However, this improvement may be due to a circularity in the data generation process leading to drug298
targets being much more likely to also be hub genes. Although genetically-informed methods performed299
better than random distributions, the STRING network node degrees resulted in the highest AUC values300
overall. Thus, care has to be taken when relying on literature-derived gene-gene interactions as ag-301
gressive diffusion will point to the same drug target genes, irrespective of the disease, and the intrinsic302
bias stemming from under- and over-studied genes may hinder the discovery of new drug targets.303
The improvements made with co-expression networks, which do not suffer from publication/curation304
biases, were minor in comparison. Although significant with the AUC metric, ORs were not significantly305
increased with a diffusion of r = 0.6 as compared to no diffusion for any of the methods.306
307
23
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
Among the set of measured proteins (which itself was enriched for drug target genes), protein levels of308
drug target genes exhibited lower heritabilities and higher polygenicities than non-drug target genes.309
The same trend, but to a lesser extent, was observed on the transcript level. Additionally, drug target310
genes had stronger network connections than non-drug target genes, even in unbiased co-expression311
networks. Together, these observations suggest a tendency for drug targets to be evolutionary312
constrained and as a result are more protected from genomic perturbations.313
314
Several limitations should be considered. First, we do not take into account directionality of therapeutic315
and genetic effects, i.e., whether the drug is an agonist or antagonist. Although found to be less316
performant than GWAS, QTL-GWAS methods have the advantage of specifying directionality, as317
opposed to gene scores from the GWAS approach which ignores SNP effect directions. Second, the318
used molecular QTL data sets cover only a small fraction of possible intermediate traits through which319
SNPs exert their disease-inducing effects [43]. Third, we only focus on common genetic variants when320
associating transcript and protein levels. With the advent of coupled rare variant-protein level data,321
either from populations enriched for rare variants or sequencing data [14, 44], more powerful QTL-322
GWAS methods are likely to emerge that combine mechanistic insights gained from QTL approaches323
while capturing rare variant associations previously missed. Fourth, drug target data are sparse which324
limits the statistical power in benchmarking analyses. Given the required resources to test a drug325
target in clinical settings, focusing on top ranking genes is of most interest. This scenario is best326
described with a threshold that defines highly prioritized genes for enrichment analyses. However,327
ROC curves that quantify the performance at all prioritization thresholds (i.e. use all data at hand)328
were better powered to detect subtle differences between methods. Finally, our analysis compares329
Methods
using historical drug discovery data as the ground truth. This data is highly biased with330
G-protein-coupled receptors being targets of a third of FDA-approved drugs [45]. Many other genes331
may be effective targets, but have never been tested in clinical trials. Thus, our results may not reflect332
how well the tested genetic approaches uncover true disease genes, but rather how well they identify333
targets that were historically prioritized in drug development processes. Since the emergence of robust334
24
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
GWAS, more and more clinical trials are motivated by genetically informed targets. Thus, drug tar-335
get databases will tend to overlap better with GWAS-inspired genes, leading to artificially higher overlap.336
337
To conclude, we systematically evaluated major gene prioritization approaches for their ability to identify338
approved drug target genes. Our analyses highlight the power of harnessing multiple data sources339
by capitalizing on QTLs for mechanistic insights, sequencing data for rare variant associations, GWAS340
when molecular QTL signals are missing and network propagation to leverage gene-gene interactions.341
Methods342
GWAS data343
We used the largest (to-date), publicly available GWAS summary statistics for each analyzed condi-344
tion (Table S1). GWAS data came mostly from consortia specific to the respective disease, and were345
often a meta-analysis comprising the UKBB. Twenty-four out of the 30 conditions were case/control346
studies, the remaining 6 being continuous traits: diastolic and systolic blood pressure (DBP and SBP , re-347
spectively [46]), low-density lipoprotein and total cholesterol (LDL and TC, respectively [47]), estimated348
glomerular filtration rate (eGFR [48]) and heel bone mineral density ([47]) proxying chronic kidney dis-349
ease (CKD) and osteoporosis, respectively. For four traits with low case count in the UK Biobank (<350
20,000; chronic obstructive pulmonary disease (COPD), endometriosis, pneumonia and psoriasis) and351
no large-scale GWAS meta-analysis available, we performed a meta-analysis between the UK Biobank352
[47] and FinnGen [49] using METAL [50].353
GWAS gene scores354
We used PascalX [9, 51] to compute gene scores based on GWAS summary statistics. The software355
takes as input GWAS p-values, gene annotations and LD structure. SNPs are assigned to genes and356
their squared z-scores are summed. This sum, under the null, was shown to follow a weighted chi-357
square distribution with weights being defined by the local LD structure from which gene p-values can be358
derived [9]. We applied PascalX with default parameters (gene ± 50 kB) on protein-coding genes using359
25
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
the Ensembl identifiers and annotations (Ensembl GRCh37.p13 version) and the UK10K reference panel360
[52]. Across traits, ∼19,150 protein-coding genes could be tested which were ranked by their PascalX361
p-value.362
Molecular QTL-GWAS gene scores363
We integrated molecular quantitative trait loci (QTL) and GWAS summary statistics using Mendelian364
randomization (MR) implemented in the smr-ivw software [53, 22]. The exposure (transcript or protein365
levels) and outcome disease were instrumented with independent genetic variants, also called instru-366
mental variables (IVs; r2 < 0.01) and used to calculate putative causal effect estimates of the exposure367
on the outcome (β MR). IVs were required to be strongly associated to the exposure (P QTL < 1e-6) and368
had to pass the Steiger filter ensuring no significantly stronger effect on the outcome than on the ex-369
posure [54]. We used expression QTLs (eQTLs) from the eQTLGen consortium [13] (whole blood; n =370
31,684) and tissue-specific QTLs from the GTEx v8 release [55] (European ancestry; n = 65-573 for 48371
tissue types; Table S4) to estimate causal transcript-trait effects. In the eQTLGen dataset there were372
∼12,550 protein-coding genes with at least 1 IV which increased to ∼16,250 when integrating the GTEx373
dataset. MR results from both datasets (whole blood from eQTLGen and 49 tissues from GTEx) were374
aggregated by considering the MR causal effect with the lowest p-value across tissues (Table S4-5).375
Protein QTLs (pQTLs) from the deCODE study [14] (whole blood; n = 35,559) were used to estimate376
protein-trait causal effects with ∼1,870 proteins having at least 1 IV. Prior to the analysis, e/pQTL and377
GWAS data were harmonized, palindromic SNPs were removed as well as SNPs with an allele frequency378
difference > 0.05 between datasets. All transcripts and proteins were mapped to Ensembl identifiers as379
provided by eQTLGen, GTEx and deCODE.380
Exome gene scores381
We used gene burden test results computed on WES data from the UK Biobank [25]. We extracted382
gene-trait associations based on putative loss of function (pLOF) and deleterious missense variants383
with MAF <1% (M3.1 nomenclature in original publication) with phenotypes matching the investigated384
conditions as indicated in Table S2. Associations were provided for ∼18,800 genes which were ranked385
26
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
by the association p-value and retrieved by the provided Ensembl identifier.386
Concordance of gene scoring methods387
We tested whether prioritized genes were similar or dissimilar between pairs of methods. First, only388
genes (based on Ensembl identifiers) that were common between the two tested methods were selected389
into the gene background. Then, prioritized genes were defined at different top percentile cut-offs (0.1%,390
0.2%, 0.5%, 1%, 2%, 3%, 5%, 7.5%, 10%). The enrichment of prioritized genes between methods was391
quantified by a Fisher’s exact test using common genes as background genes. When calculating median392
ORs, ORs of traits for which no prioritized genes overlapped at a given percentile were set to 1.393
Drug target genes394
We extracted drug target genes from public resources by combining drug-indication and drug-target links395
from various databases. A given disease/indication was linked to a drug if the drug was indicated to be396
prescribed for the selected indication and subsequently, the target genes of these drugs were extracted.397
For drug-indication pairs we consulted DrugBank, Ruiz et al. and ChEMBL:398
• DrugBank 5.0 [35] (download: May 2022): DrugBank indications are manually curated from drug399
labels and underwent an expert review process. Drug indications have their own DrugBank condi-400
tion numbers and drugs their DrugBank identifiers.401
• Ruiz et al. [36]: A drug-disease dataset was created by querying multiple sources such as the402
Drug Repurposing Database, the Drug Repurposing Hub, and the Drug Indication Database and403
extracting information from drug labels, DrugBank and the American Association of Clinical Tri-404
als Database. Drug–disease pairs were filtered for FDA-approved treatment relationships. This405
dataset uses NLM UMLS CUIDS identifiers (National Library of Medicine -Unified Medical Lan-406
guage System Controlled Unique Identifier) for diseases and DrugBank identifiers for drugs.407
• ChEMBL [37] (download: May 2022): ChEMBL drug indications are extracted from multiple408
sources including DailyMed package inserts, Anatomical Therapeutic Chemical (ATC) classifica-409
tion and ClinicalTrials.gov. Mapping of disease terms to Medical Subject Headings (MeSH) vocab-410
27
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
ulary and the Experimental Factor Ontology (EFO) is done through a combination of text-mining,411
automated mapping and manual curation/validation. Drugs are reported with ChEMBL identifiers.412
The mapping of GWAS traits to the drug indication identifiers of the respective database is shown in413
Table S6.414
415
Drug target genes were extracted from the DGIdb, STITCH and ChEMBL databases:416
• Drug Gene Interaction database (DGIdb) 4.0 [38] (release: January 2021): Aggregated drug-gene417
interactions from multiple sources including DrugBank, Drug Target Commons, the Therapeutic418
Target Database and Guide to Pharmacology. Genes were matched to Ensembl identifiers using419
the provided gene vocabulary file. Drugs were reported through DrugBank or ChEMBL identifiers,420
and mapping from ChEMBL to DrugBank identifiers was done with UniChem [56], using PubChem421
IDs as intermediates.422
• Search Tool for Interacting CHemicals (STITCH) 5.0 [39]: Aggregated drug-protein interaction423
data from high-throughput experiments data, manually curated datasets and prediction methods.424
Only high confidence drug-protein relationships (confidence score ≥ 700) of the type “inhibition”425
and “activation” were considered. STITCH uses PubChem Chemical Identifiers (CID) for drugs426
and mapping to DrugBank IDs was done through the chemical sources file provided by STITCH.427
Protein Ensembl identifiers were mapped to gene Ensembl identifiers using biomaRt (GRCh37,428
v2.50.3)[57].429
• ChEMBL [37] (download: May 2022): ChEMBL provides drug targets which have been manually430
curated from literature. Drug targets are identified by ChEMBL IDs with mapping to UniProt Ac-431
cessions provided by ChEMBL. UniProt identifiers were then mapped to gene Ensembl identifiers432
through the UniProt REST API [58].433
In this analysis we considered drug target genes resulting from the following combinations: Drug-434
Bank/DGIdb, DrugBank/STITCH, Ruiz/DGIdb, Ruiz/STITCH, and ChEMBL/ChEMBL. The number of435
drugs and drug target genes per indication is shown in Table S7.436
28
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
Drug target enrichment and AUC calculations437
Enrichment for drug target genes was calculated through two-sided Fisher’s exact tests. A contingency438
table was constructed based on testable genes (i.e., background genes), with genes categorized439
into prioritized (top 1% or 5% for the pQTL-GWAS) and drug target genes. In rare instances (i.e.,440
pQTL-GWAS background genes and ChEMBL/ChEMBL drug targets) where diagonal values were 0,441
these were changed to 1. If no prioritized gene coincided with a drug target gene, the resulting OR442
was set to 1 (for visualization purposes this was not done in barplots where each trait was shown443
individually). AUC values and standard errors were calculated using the R package pROC v1.15.3 [59].444
445
Log-OR and AUC values (both are denotedbi herein) were aggregated across traits and drug databases446
(m = 30 · 5 = 150 observations per method) as follows:447
¯b = 1
m
mX
i
bi (1)
with corresponding variance:448
var(¯b) = 1′ · S · R · S · 1/m2 (2)
where S is a diagonal matrix of size mxm containing standard errors of bi and R is the correlation449
matrix between drug databases and traits. This matrix was derived from the Kronecker product of the450
drug database correlation matrix and phenotypic trait correlation matrix (Table S8). The drug database451
correlation matrix was derived on the gene level (i.e., 1 if the gene was a drug target for any of the 30452
traits, 0 if not) and the phenotypic trait correlation on individual-level data from the UKBB (codes in Table453
S2). ¯b was referred to as the overall AUC/ log-OR (overall OR after an exponential transformation).454
455
To calculate the statistical difference of ¯b1 and ¯b2 for method 1 and 2, respectively, we derived the456
variance of the difference as follows:457
29
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
var(¯b1 − ¯b2) = var(¯b1) + var(¯b2) − 2 · cov(¯b1,¯b2) (3)
with cov(¯b1,¯b2) ≈ r ×
1′ · S1 · R · S2 · 1/m2
, where r is the empirical correlation between b1 and b2.458
From the resulting z-score, a two-sided p-value was calculated.459
Transcript and protein level heritabilities and polygenicity460
Transcript and protein level heritabilities were estimated from QTL effects. Standardized QTL effects461
( ˆβG) were approximated by dividing SNP z-scores by the square root of the sample size. The corre-462
sponding variance (var( ˆβG)) equals the inverse of the sample size. The cis heritability (ˆh2
cis) could then463
be estimated by summing up effects of independent (r 2 < 0.01) and significant (p-value < 1e-6) QTLs464
in proximity of the transcript/protein (± 500 kB) while taking into account their variance:465
ˆh2
cis =
X
i
ˆβ2
Gi − var(ˆβGi)
(4)
Protein heritabilities were based on the deCODE plasma protein dataset [14] and transcript heritabilities466
for whole blood on the eQTLGen dataset [13]. Tissue-wide transcript heritabilities were based on eQTL467
effects from the tissue in which the MR effect was the most significant [55].468
469
To calculate the difference in heritabilities and polygenicities between drug target and non-drug target470
genes, we considered all transcripts and proteins measured in the respective study which were classified471
accordingly. Per trait, the difference in heritability was then calculated through a two-sided t-test. For472
the polygenicity analysis, we considered the number of independent (r2 < 0.01) and significant (p-value473
< 1e-6) QTLs associated to a transcript/protein. Note that this proxy for polygenicity is biased, as474
for less heritable omics entities we have less power to detect the independent signals, and may look475
less polygenic. We then conducted two-sided Wilcoxon tests to determine the difference in number of476
instrumental variables (IVs). Heritability and polygenicity tests were only performed for traits with at477
least three drug targets within the respective set of measured transcripts/proteins. Note that in case a478
30
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
transcript or protein was reported as measured in the study, but had no associated QTL, its heritability479
and number of IVs were set to zero.480
Networks481
To calculate network diffusion scores, we used the following three networks:482
• Search Tool for Retrieval of Interacting Genes/Proteins (STRING) v11 [32]: The protein-protein483
(PPI) interaction network results from predictions based on genomic context information, co-484
expression, text-mining, experimental biochemical/genetic data and curated databases (curated485
pathways and protein-complex knowledge). Protein Ensembl identifiers were mapped to gene En-486
sembl identifiers using biomaRt (GRCh37, v2.50.3)[57]. We use interaction confidence scores as487
edge weights.488
• CoXRNAseq [33]: This network was constructed by first performing a principal component analy-489
sis on the gene co-expression correlation matrix of 31,499 RNA-seq samples. Reliable principal490
components were retained from which the final network was constructed via Pearson correlations.491
We filtered pairwise interactions to only retain those with z-scores above 4. Genes were reported492
with Ensembl identifiers and z-scores were used as edge weights.493
• Functional Associations using Variational Autoencoders (FAVA) [34]: This network is based on494
single cell RNA-seq read-count data from the Human Protein Atlas and proteomics data from the495
PRoteomics IDEntifications (PRIDE) database. First, the high-dimensional expression data was496
reduced into a latent space using variational autoencoders. From this latent space, the network497
was derived via pairwise Pearson correlations. Each reported interaction has a score which we498
use as edge weight (final network reports interactions with scores above 0.15). Protein Ensembl499
identifiers were mapped to gene Ensembl identifiers using biomaRt.500
A summary of network properties is given in Table S11. In all analyses, we use weighted networks, and501
we refer to weighted node degrees (i.e., sum of edge weights linking the node of interest to adjacent502
nodes) as node degrees.503
31
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
Network diffusion504
We calculated network diffusion scores based on Markov random walks. Starting from an initial node505
distribution p0, a stationary distribution is calculated based on network connectivity. This diffusion pro-506
cess depends on a restart parameter r which determines how often the random walker returns to the507
initial values. Analytically, the stationary distribution (p∞) is given by:508
p∞ = (I − (1 − r) · W )−1 · p0 (5)
where W is the column-normalized weighted adjacency matrix and I the identity matrix of the same509
dimension as W [60]. The initial node distribution p0 was determined by the squared z-scores derived510
from the gene p-values (normalized to sum up to 1). Genes that could not be tested by a given method511
had their initial value set to 0. Additionally, we tested the performance of network diffusion on random512
initial distributions p0. For each trait, a random distribution was generated which all were different, but513
consistent across analyses. Resulting network diffusion scores p∞ were ranked for AUC calculations,514
and the top 1% scored genes were used in the enrichment analyses.515
516
Network manipulations, visualization and degree calculations were performed with the R igraph package517
v1.3.5 [61].518
Enrichment of available proteins for drug targets519
We conducted binomial tests to verify whether the set of testable (i.e., at least 1 pQTL) and measured520
proteins ( ∼1,870 and ∼4,450, respectively) were enriched for drug target genes. We performed the521
analysis on each of the five drug target definitions and proceeded as follows: 1) we extracted the number522
of testable/measured proteins that are drug targets (“number of successes”), 2) considering all protein-523
coding autosomal genes (19,430), we extracted those that are drug targets (“number of trials”), 3) we524
determined the proportion of testable/measured proteins among all protein-coding genes (“expected525
probability of success”). From these numbers, we conducted two-sided exact binomial tests (Table526
32
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
S15).527
Data availability
Whole blood expression QTLs are from the eQTLGen eQTL meta-analysis and are available at https:
//www.eqtlgen.org/cis-eqtls.html. Tissue-wide expression QTLs are from the GTEx project and
are available at https://gtexportal.org/home/datasets. Plasma protein QTLs are from the de-
CODE study and are available at https://www.decode.com/summarydata/. Summary statistics from
whole exome gene burden tests are available in the GWAS Catalog (accession IDs are in Table S2).
Genetic and phenotypic data from the UK Biobank Resource are available to approved researchers.
GWAS summary statistics from the UK Biobank are available athttp://www.nealelab.is/uk-biobank
and https://pan.ukbb.broadinstitute.org. GWAS summary statistics from FinnGen are available at
https://www.finngen.fi/en/access_results. GWAS summary statistics for multiple sclerosis (MS)
are available by application from https://imsgc.net/?page_id=31. Full list of GWAS summary statis-
tics used in this study is in Table S1-3, all of which are publicly available. UK10K individual-level data
are available upon request (https://www.uk10k.org/data_access.html).
Code availability
GWAS calculations were performed with REGENIE which is available athttps://github.com/rgcgithub/
regenie. GWAS meta-analyses were performed with METAL which is available at https://github.
com/statgen/METAL. Gene scoring was performed with the PascalX software which is available at
https://github.com/BergmannLab/PascalX. QTL Mendelian randomization analyses were performed
with the SMR-IVW software which is available at https://github.com/masadler/smrivw.
Competing interests
The authors declare that they have no competing interests.
33
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
Authors’ contributions
MCS and ZK conceived and designed the study. MCS performed statistical analyses. PD provided
guidance on statistical analyses. ZK supervised all statistical analyses. CA contributed to the collection
and interpretation of pharmacological and biological data. All the authors contributed by providing advice
on interpretation of results. MCS and ZK drafted the manuscript. All authors read, approved, and
provided feedback on the final manuscript.
Acknowledgements
This work was supported by the Swiss National Science Foundation (310030
189147) to Z.K. This re-
search has been conducted using the UK Biobank Resource under Application Number 16389. LD
was calculated based on the UK10K data resource (EGAD00001000740, EGAD00001000741). Com-
putations we performed on the JURA cluster of the University of Lausanne. We also would like to
acknowledge the participants and investigators of the UK Biobank and FinnGen study. We thank Daniel
Krefl for his help and support in implementing the PascalX software and Liza Darrous for critical reading
of the draft.
References
[1] Matthew R Nelson, Hannah Tipney, Jeffery L Painter, Judong Shen, Paola Nicoletti, Yufeng Shen,
Aris Floratos, Pak Chung Sham, Mulin Jun Li, Junwen Wang, et al. The support of human genetic
evidence for approved drug indications. Nature genetics, 47(8):856–860, 2015.
[2] Emily A King, J Wade Davis, and Jacob F Degner. Are drug targets with genetic support twice as
likely to be approved? revised estimates of the impact of genetic support for drug mechanisms on
the probability of drug approval. PLoS genetics, 15(12):e1008489, 2019.
[3] Stacey L Edwards, Jonathan Beesley, Juliet D French, and Alison M Dunning. Beyond gwass:
illuminating the dark road from association to function. The American Journal of Human Genetics,
93(5):779–797, 2013.
34
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
[4] Chen Cao and John Moult. Gwas and drug targets. BMC genomics, 15(4):1–14, 2014.
[5] Vivian Tam, Nikunj Patel, Michelle Turcotte, Y ohan Boss´e, Guillaume Par´e, and David Meyre. Bene-
fits and limitations of genome-wide association studies. Nature Reviews Genetics, 20(8):467–484,
2019.
[6] Steven Gazal, Omer Weissbrod, Farhad Hormozdiari, Kushal K Dey, Joseph Nasser, Karthik A
Jagadeesh, Daniel J Weiner, Huwenbo Shi, Charles P Fulco, Luke J O’Connor, et al. Combining
snp-to-gene linking strategies to identify disease genes and assess disease omnigenicity. Nature
Genetics, pages 1–10, 2022.
[7] Jimmy Z Liu, Allan F Mcrae, Dale R Nyholt, Sarah E Medland, Naomi R Wray, Kevin M Brown,
Nicholas K Hayward, Grant W Montgomery, Peter M Visscher, Nicholas G Martin, et al. A versatile
gene-based test for genome-wide association studies. The American Journal of Human Genetics,
87(1):139–145, 2010.
[8] Christiaan A de Leeuw, Joris M Mooij, Tom Heskes, and Danielle Posthuma. Magma: generalized
gene-set analysis of gwas data. PLoS computational biology, 11(4):e1004219, 2015.
[9] David Lamparter, Daniel Marbach, Rico Rueedi, Zolt ´an Kutalik, and Sven Bergmann. Fast and
rigorous computation of gene and pathway scores from snp-based summary statistics. PLoS com-
putational biology, 12(1):e1004714, 2016.
[10] John Lonsdale, Jeffrey Thomas, Mike Salvatore, Rebecca Phillips, Edmund Lo, Saboor Shad,
Richard Hasz, Gary Walters, Fernando Garcia, Nancy Y oung, et al. The genotype-tissue expres-
sion (gtex) project. Nature genetics, 45(6):580–585, 2013.
[11] Benjamin B Sun, Joseph C Maranville, James E Peters, David Stacey, James R Staley, James
Blackshaw, Stephen Burgess, Tao Jiang, Ellie Paige, Praveen Surendran, et al. Genomic atlas of
the human plasma proteome. Nature, 558(7708):73–79, 2018.
[12] Lasse Folkersen, Stefan Gustafsson, Qin Wang, Daniel Hvidberg Hansen, ˚Asa K Hedman, Andrew
Schork, Karen Page, Daria V Zhernakova, Y ang Wu, James Peters, et al. Genomic and drug target
35
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
evaluation of 90 cardiovascular proteins in 30,931 individuals. Nature metabolism, 2(10):1135–
1148, 2020.
[13] Urmo V ˜osa, Annique Claringbould, Harm-Jan Westra, Marc Jan Bonder, Patrick Deelen, Biao Zeng,
Holger Kirsten, Ashis Saha, Roman Kreuzhuber, Harm Brugge, et al. Large-scale cis-and trans-
eqtl analyses identify thousands of genetic loci and polygenic scores that regulate blood gene
expression. Nature genetics, pages 1–11, 2021.
[14] Egil Ferkingstad, Patrick Sulem, Bjarni A Atlason, Gardar Sveinbjornsson, Magnus I Magnusson,
Edda L Styrmisdottir, Kristbjorg Gunnarsdottir, Agnar Helgason, Asmundur Oddsson, Bjarni V Hall-
dorsson, et al. Large-scale integration of the plasma proteome with genetics and disease. Nature
Genetics, 53(12):1712–1721, 2021.
[15] Benjamin B Sun, Joshua Chiou, Matthew Traylor, Christian Benner, Yi-Hsiang Hsu, Tom G Richard-
son, Praveen Surendran, Anubha Mahajan, Chloe Robins, Steven G Vasquez-Grinnell, et al. Ge-
netic regulation of the human plasma proteome in 54,306 uk biobank participants. BioRxiv, 2022.
[16] Claudia Giambartolomei, Damjan Vukcevic, Eric E Schadt, Lude Franke, Aroon D Hingorani, Chris
Wallace, and Vincent Plagnol. Bayesian test for colocalisation between pairs of genetic association
studies using summary statistics. PLoS Genet, 10(5):e1004383, 2014.
[17] Farhad Hormozdiari, Martijn Van De Bunt, Ayellet V Segre, Xiao Li, Jong Wha J Joo, Michael Bilow,
Jae Hoon Sul, Sriram Sankararaman, Bogdan Pasaniuc, and Eleazar Eskin. Colocalization of gwas
and eqtl signals detects target genes.The American Journal of Human Genetics, 99(6):1245–1260,
2016.
[18] Alexander Gusev, Arthur Ko, Huwenbo Shi, Gaurav Bhatia, Wonil Chung, Brenda WJH Penninx,
Rick Jansen, Eco JC De Geus, Dorret I Boomsma, Fred A Wright, et al. Integrative approaches for
large-scale transcriptome-wide association studies. Nature genetics, 48(3):245–252, 2016.
[19] Alvaro N Barbeira, Scott P Dickinson, Rodrigo Bonazzola, Jiamao Zheng, Heather E Wheeler,
Jason M Torres, Eric S Torstenson, Kaanan P Shah, Tzintzuni Garcia, Todd L Edwards, et al.
36
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
Exploring the phenotypic consequences of tissue specific gene expression variation inferred from
gwas summary statistics. Nature communications, 9(1):1–20, 2018.
[20] Y ang Wu, Jian Zeng, Futao Zhang, Zhihong Zhu, Ting Qi, Zhili Zheng, Luke R Lloyd-Jones, Ric-
cardo E Marioni, Nicholas G Martin, Grant W Montgomery, et al. Integrative analysis of omics
summary data reveals putative mechanisms underlying complex traits. Nature communications,
9(1):1–14, 2018.
[21] Eleonora Porcu, Sina R ¨ueger, Kaido Lepik, Federico A Santoni, Alexandre Reymond, and Zolt ´an
Kutalik. Mendelian randomization integrating gwas and eqtl data reveals genetic determinants of
complex and clinical traits. Nature communications, 10(1):1–12, 2019.
[22] Marie C Sadler, Chiara Auwerx, Kaido Lepik, Eleonora Porcu, and Zolt ´an Kutalik. Quantifying the
role of transcript levels in mediating dna methylation effects on complex traits and diseases.Nature
Communications, 13(1):1–14, 2022.
[23] Elizabeth T Cirulli, Simon White, Robert W Read, Gai Elhanan, William J Metcalf, Francisco Tanud-
jaja, Donna M Fath, Efren Sandoval, Magnus Isaksson, Karen A Schlauch, et al. Genome-wide
rare variant analysis for thousands of phenotypes in over 70,000 exomes from two cohorts. Nature
communications, 11(1):1–10, 2020.
[24] Jack A Kosmicki, Julie E Horowitz, Nilanjana Banerjee, Rouel Lanche, Anthony Marcketta, Evan
Maxwell, Xiaodong Bai, Dylan Sun, Joshua D Backman, Deepika Sharma, et al. Pan-ancestry
exome-wide association analyses of covid-19 outcomes in 586,157 individuals. The American
Journal of Human Genetics, 108(7):1350–1355, 2021.
[25] Joshua D Backman, Alexander H Li, Anthony Marcketta, Dylan Sun, Joelle Mbatchou, Michael D
Kessler, Christian Benner, Daren Liu, Adam E Locke, Suganthi Balasubramanian, et al. Exome
sequencing and analysis of 454,787 uk biobank participants. Nature, 599(7886):628–634, 2021.
[26] Emre Guney, J ¨org Menche, Marc Vidal, and Albert-L ´aszl´o Bar´abasi. Network-based in silico drug
efficacy screening. Nature communications, 7(1):1–13, 2016.
37
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
[27] Hai Fang, Hans De Wolf, Bogdan Knezevic, Katie L Burnham, Julie Osgood, Anna Sanniti, Alicia
Lled´o Lara, Silva Kasela, Stephane De Cesco, J ¨org K Wegner, et al. A genetics-led approach
defines the drug target landscape of 30 immune-related traits. Nature genetics, 51(7):1082–1091,
2019.
[28] Aidan MacNamara, Nikolina Nakic, Ali Amin Al Olama, Cong Guo, Karsten B Sieber, Mark R Hurle,
and Alex Gutteridge. Network and pathway expansion of genetic disease associations identifies
successful drug targets. Scientific reports, 10(1):1–11, 2020.
[29] Yingnan Han, Clarence Wang, Katherine Klinger, Deepak K Rajpal, and Cheng Zhu. An integrative
network-based approach for drug target indication expansion. PloS one, 16(7):e0253614, 2021.
[30] Inigo Barrio-Hernandez, Jeremy Schwartzentruber, Anjali Shrivastava, Noemi del Toro, Qian
Zhang, Glyn Bradley, Henning Hermjakob, Sandra Orchard, Ian Dunham, Carl A Anderson, et al.
Network expansion of genetic associations defines a pleiotropy map of human cell biology.BioRxiv,
2021.
[31] Katja Luck, Dae-Kyum Kim, Luke Lambourne, Kerstin Spirohn, Bridget E Begg, Wenting Bian, Ruth
Brignall, Tiziana Cafarelli, Francisco J Campos-Laborie, Benoit Charloteaux, et al. A reference map
of the human binary protein interactome. Nature, 580(7803):402–408, 2020.
[32] Damian Szklarczyk, Annika L Gable, David Lyon, Alexander Junge, Stefan Wyder, Jaime Huerta-
Cepas, Milan Simonovic, Nadezhda T Doncheva, John H Morris, Peer Bork, et al. String v11:
protein–protein association networks with increased coverage, supporting functional discovery in
genome-wide experimental datasets. Nucleic acids research, 47(D1):D607–D613, 2019.
[33] Patrick Deelen, Sipko van Dam, Johanna C Herkert, Juha M Karjalainen, Harm Brugge, Kristin M
Abbott, Cleo C van Diemen, Paul A van der Zwaag, Erica H Gerkes, Evelien Zonneveld-Huijssoon,
et al. Improving the diagnostic yield of exome-sequencing by predicting gene–phenotype associa-
tions using large-scale gene expression analysis. Nature communications, 10(1):1–13, 2019.
38
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
[34] Mikaela Koutrouli, Pau Piera L ´ındez, Robbin Bouwmeester, Lennart Martens, and Lars Juhl
Jensen. Fava: High-quality functional association networks inferred from scrna-seq and proteomics
data. bioRxiv, 2022.
[35] David S Wishart, Y annick D Feunang, An C Guo, Elvis J Lo, Ana Marcu, Jason R Grant, Tanvir
Sajed, Daniel Johnson, Carin Li, Zinat Sayeeda, et al. Drugbank 5.0: a major update to the
drugbank database for 2018. Nucleic acids research, 46(D1):D1074–D1082, 2018.
[36] Camilo Ruiz, Marinka Zitnik, and Jure Leskovec. Identification of disease treatment mechanisms
through the multiscale interactome. Nature communications, 12(1):1–15, 2021.
[37] Anna Gaulton, Anne Hersey, Michał Nowotka, A Patricia Bento, Jon Chambers, David Mendez,
Prudence Mutowo, Francis Atkinson, Louisa J Bellis, Elena Cibri ´an-Uhalte, et al. The chembl
database in 2017. Nucleic acids research, 45(D1):D945–D954, 2017.
[38] Sharon L Freshour, Susanna Kiwala, Kelsy C Cotto, Adam C Coffman, Joshua F McMichael,
Jonathan J Song, Malachi Griffith, Obi L Griffith, and Alex H Wagner. Integration of the drug–
gene interaction database (dgidb 4.0) with open crowdsource efforts. Nucleic acids research,
49(D1):D1144–D1151, 2021.
[39] Damian Szklarczyk, Alberto Santos, Christian Von Mering, Lars Juhl Jensen, Peer Bork, and
Michael Kuhn. Stitch 5: augmenting protein–chemical interaction networks with tissue and affinity
data. Nucleic acids research, 44(D1):D380–D384, 2016.
[40] Luke J O’Connor, Armin P Schoech, Farhad Hormozdiari, Steven Gazal, Nick Patterson, and
Alkes L Price. Extreme polygenicity of complex traits is explained by negative selection. The
American Journal of Human Genetics, 105(3):456–476, 2019.
[41] Edward Mountjoy, Ellen M Schmidt, Miguel Carmona, Jeremy Schwartzentruber, Gareth Peat, Al-
fredo Miranda, Luca Fumis, James Hayhurst, Annalisa Buniello, Mohd Anisul Karim, et al. An
open approach to systematically prioritize causal variants and genes at all published human gwas
trait-associated loci. Nature Genetics, 53(11):1527–1533, 2021.
39
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
[42] Vincenzo Forgetta, Lai Jiang, Nicholas A Vulpescu, Megan S Hogan, Siyuan Chen, John A Morris,
Stepan Grinek, Christian Benner, Dong-Keun Jang, Quy Hoang, et al. An effector index to predict
target genes at gwas loci. Human Genetics, pages 1–17, 2022.
[43] Douglas W Y ao, Luke J O’Connor, Alkes L Price, and Alexander Gusev. Quantifying genetic effects
on disease mediated by assayed gene expression levels. Nature Genetics, 52(6):626–633, 2020.
[44] Ryan S Dhindsa, Oliver S Burren, Benjamin B Sun, Bram P Prins, Dorota Matelska, Eleanor
Wheeler, Jonathan Mitchell, Erin Oerton, Ventzislava A Hristova, Katherine R Smith, et al. Influ-
ences of rare protein-coding genetic variants on the human plasma proteome in 50,829 uk biobank
participants. bioRxiv, 2022.
[45] Alexander S Hauser, Sreenivas Chavali, Ikuo Masuho, Leonie J Jahn, Kirill A Martemyanov, David E
Gloriam, and M Madan Babu. Pharmacogenomics of gpcr drug targets.Cell, 172(1-2):41–54, 2018.
[46] Evangelos Evangelou, Helen R Warren, David Mosen-Ansorena, Borbala Mifsud, Raha Pazoki,
He Gao, Georgios Ntritsos, Niki Dimou, Claudia P Cabrera, Ibrahim Karaman, et al. Genetic anal-
ysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nature
genetics, 50(10):1412–1425, 2018.
[47] Clare Bycroft, Colin Freeman, Desislava Petkova, Gavin Band, Lloyd T Elliott, Kevin Sharp, Allan
Motyer, Damjan Vukcevic, Olivier Delaneau, Jared O’Connell, et al. The UK Biobank resource with
deep phenotyping and genomic data. Nature, 562(7726):203–209, 2018.
[48] Matthias Wuttke, Y ong Li, Man Li, Karsten B Sieber, Mary F Feitosa, Mathias Gorski, Adrienne Tin,
Lihua Wang, Audrey Y Chu, Anselm Hoppmann, et al. A catalog of genetic loci associated with
kidney function from analyses of a million individuals. Nature genetics, 51(6):957–972, 2019.
[49] Mitja I Kurki, Juha Karjalainen, Priit Palta, Timo P Sipil ¨a, Kati Kristiansson, Kati Donner, Mary P
Reeve, Hannele Laivuori, Mervi Aavikko, Mari A Kaunisto, et al. Finngen: Unique genetic insights
from combining isolated population and national health register data. medRxiv, 2022.
40
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
[50] Cristen J Willer, Yun Li, and Gonc ¸alo R Abecasis. Metal: fast and efficient meta-analysis of
genomewide association scans. Bioinformatics, 26(17):2190–2191, 2010.
[51] Daniel Krefl and Sven Bergmann. Bergmannlab/pascalx: Pascalx v0.0.1 (v0.0.1), 2021. https:
//doi.org/10.5281/zenodo.4429922.
[52] UK10K et al. The UK10K project identifies rare variants in health and disease. Nature,
526(7571):82, 2015.
[53] Zhihong Zhu, Futao Zhang, Han Hu, Andrew Bakshi, Matthew R Robinson, Joseph E Powell,
Grant W Montgomery, Michael E Goddard, Naomi R Wray, Peter M Visscher, et al. Integration
of summary data from gwas and eqtl studies predicts complex trait gene targets. Nature genetics,
48(5):481–487, 2016.
[54] Gibran Hemani, Kate Tilling, and George Davey Smith. Orienting the causal relationship between
imprecisely measured traits using GWAS summary data. PLoS genetics, 13(11):e1007081, 2017.
[55] THE GTEX CONSORTIUM. The GTEx Consortium atlas of genetic regulatory effects across hu-
man tissues. Science, 369(6509):1318–1330, 2020.
[56] Jon Chambers, Mark Davies, Anna Gaulton, Anne Hersey, Sameer Velankar, Robert Petryszak,
Janna Hastings, Louisa Bellis, Shaun McGlinchey, and John P Overington. Unichem: a unified
chemical structure cross-referencing and identifier tracking system. Journal of cheminformatics,
5(1):1–9, 2013.
[57] Steffen Durinck, Paul T. Spellman, Ewan Birney, and Wolfgang Huber. Mapping identifiers for
the integration of genomic datasets with the r/bioconductor package biomart. Nature Protocols,
4:1184–1191, 2009.
[58] Andrew Nightingale, Ricardo Antunes, Emanuele Alpi, Borisas Bursteinas, Leonardo Gonzales,
Wudong Liu, Jie Luo, Guoying Qi, Edd Turner, and Maria Martin. The proteins api: accessing key
integrated protein and genome information. Nucleic acids research, 45(W1):W539–W544, 2017.
41
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
[59] Xavier Robin, Natacha Turck, Alexandre Hainard, Natalia Tiberti, Fr´ed´erique Lisacek, Jean-Charles
Sanchez, and Markus M ¨uller. proc: an open-source package for r and s+ to analyze and compare
roc curves. BMC bioinformatics, 12(1):1–8, 2011.
[60] Hanghang Tong, Christos Faloutsos, and Jia-Yu Pan. Fast random walk with restart and its appli-
cations. In Sixth international conference on data mining (ICDM’06), pages 613–622. IEEE, 2006.
[61] Gabor Csardi, Tamas Nepusz, et al. The igraph software package for complex network research.
InterJournal, complex systems, 1695(5):1–9, 2006.
42
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.